Plasma convalescente como alternativa ao tratamento aplicado à Covid-19
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , , , , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Revista Brasileira Multidisciplinar |
Texto Completo: | http://revistarebram.com/index.php/revistauniara/article/view/1153 |
Resumo: | COVID-19 is an infectious disease that has spread rapidly around the world, characterizing a pandemic. Its etiologic agent is SARS-CoV-2, which promotes respiratory infections, mainly with symptoms equivalent to the common cold, but also complications, especially in patients with comorbidities. So far, there are no reports of medication, available to the population, capable of controlling the proliferation of the virus. In this context, an alternative that emerges and is also being discussed is the use of convalescent plasma (CP). Therefore, this study aimed to present a possible therapeutic resource for the care of patients infected with SARS-CoV-2 using CP, based on evidences from the literature. To achieve this goal, databases, such as Google Scholar, Scielo, Science Direct and PubMed, were used to search for evidences. Among the keywords used can be mentioned: “Coronavirus”, “COVID-19”, “SARS-CoV-2”, “convalescent plasma” isolated or in combination. The CP consists of plasma from patients who have already had the disease and recovered, serving as a source of specific antibodies of human origin, since there was the development of humoral immunization against the infectious agent. Therefore, in this case, the intention is to perform a CP transfusion for patients who are sick, neutralizing the pathogen and eventually leading to its eradication of blood circulation, since the antibody circulates in the blood, reaches tissues and protects against infections. There are not many studies available in the literature on the topic yet, but they already show promising results, including those associated with previous evidence of other viral infections such as Ebola, H5N1, H1N1 and measles. It is concluded that convalescent plasma may be a potential therapy for patients infected with SARS-CoV-2 with the highest risk involved. Serious adverse reactions associated with the use of CP have not been described, but an improvement in the condition compared to no treatment. |
id |
UNIARA_6d933b5beecf21ad0d757daf9e98780f |
---|---|
oai_identifier_str |
oai:ojs.revistarebram.com:article/1153 |
network_acronym_str |
UNIARA |
network_name_str |
Revista Brasileira Multidisciplinar |
repository_id_str |
|
spelling |
Plasma convalescente como alternativa ao tratamento aplicado à Covid-19COVID-19 is an infectious disease that has spread rapidly around the world, characterizing a pandemic. Its etiologic agent is SARS-CoV-2, which promotes respiratory infections, mainly with symptoms equivalent to the common cold, but also complications, especially in patients with comorbidities. So far, there are no reports of medication, available to the population, capable of controlling the proliferation of the virus. In this context, an alternative that emerges and is also being discussed is the use of convalescent plasma (CP). Therefore, this study aimed to present a possible therapeutic resource for the care of patients infected with SARS-CoV-2 using CP, based on evidences from the literature. To achieve this goal, databases, such as Google Scholar, Scielo, Science Direct and PubMed, were used to search for evidences. Among the keywords used can be mentioned: “Coronavirus”, “COVID-19”, “SARS-CoV-2”, “convalescent plasma” isolated or in combination. The CP consists of plasma from patients who have already had the disease and recovered, serving as a source of specific antibodies of human origin, since there was the development of humoral immunization against the infectious agent. Therefore, in this case, the intention is to perform a CP transfusion for patients who are sick, neutralizing the pathogen and eventually leading to its eradication of blood circulation, since the antibody circulates in the blood, reaches tissues and protects against infections. There are not many studies available in the literature on the topic yet, but they already show promising results, including those associated with previous evidence of other viral infections such as Ebola, H5N1, H1N1 and measles. It is concluded that convalescent plasma may be a potential therapy for patients infected with SARS-CoV-2 with the highest risk involved. Serious adverse reactions associated with the use of CP have not been described, but an improvement in the condition compared to no treatment.A COVID-19 é uma doença infecciosa, que se espalhou rapidamente no mundo, caracterizando uma pandemia. Tem como agente etiológico o SARS-CoV-2, que promove infecções respiratórias, principalmente, com sintomas equivalentes ao do resfriado comum, mas também, complicações principalmente em pacientes com comorbidades. Até o momento não existem relatos de medicamento, disponível para a população, capaz de controlar a proliferação do vírus. Neste contexto, uma alternativa que emerge e também vem sendo discutida é a utilização de plasma convalescente (PC). Assim sendo, este trabalho teve como objetivo apresentar um possível recurso terapêutico para o cuidado de pacientes infectados pelo SARS-CoV-2 utilizando PC, com base em evidências da literatura. Para alcançar este objetivo, bases de dados, como Google Acadêmico, Scielo, Science Direct e PubMed, foram utilizadas na busca de evidências. Dentre os unitermos utilizados podem ser citados: “Coronavirus”, “COVID-19”, “SARS-CoV-2”, “convalescent plasma” isolados ou em combinação. O PC consiste em plasma de pacientes que já tiveram a doença e se recuperaram servindo como fonte de anticorpos específicos de origem humana, uma vez que houve o desenvolvimento de imunização humoral contra o agente infeccioso. Portanto, neste caso, a intenção é realizar a transfusão de PC para pacientes que estão doentes neutralizando o patógeno e, eventualmente, levando à sua erradicação da circulação sanguínea, já que o anticorpo circula no sangue, atinge tecidos e protege contra infecções. Ainda não existem muitos trabalhos disponíveis na literatura sobre o tema mas já mostram resultados promissores, inclusive associados com evidências anteriores de outras infecções virais como Ebola, H5N1, H1N1 e do sarampo. Conclui-se que o plasma convalescente pode ser uma terapia potencial para pacientes infectados com SARS-CoV-2 com maior risco envolvido. Não foram descritas reações adversas graves associadas à utilização de PC, mas melhoria do quadro em comparação ao não tratamento. Revista Brasileira Multidisciplinar - ReBraM2020-09-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://revistarebram.com/index.php/revistauniara/article/view/115310.25061/2527-2675/ReBraM/2020.v23i3.1153Revista Brasileira Multidisciplinar - ReBraM; v. 23 n. 3 (2020): Setembro-Dezembro; 244-2582527-26751415-3580reponame:Revista Brasileira Multidisciplinarinstname:Universidade de Araraquara (UNIARA)instacron:UNIARAporhttp://revistarebram.com/index.php/revistauniara/article/view/1153/645dos santos, Isabela BarbosaVieira Borrasca , Julia Rodrigues Tiera, Lara de OliveiraGarcia, LarissaGuidorizzi Advíncula , Marina Giachini Segantini, Thainá Marques de Mendonça, Thaís MarquesChiari-Andréo, Bruna Galdorfiniinfo:eu-repo/semantics/openAccess2021-03-06T03:18:34Zoai:ojs.revistarebram.com:article/1153Revistahttp://revistarebram.com/index.php/revistauniaraPRIhttps://revistarebram.com/index.php/revistauniara/oairevistauniara@uniara.com||2527-26752527-2675opendoar:2021-03-06T03:18:34Revista Brasileira Multidisciplinar - Universidade de Araraquara (UNIARA)false |
dc.title.none.fl_str_mv |
Plasma convalescente como alternativa ao tratamento aplicado à Covid-19 |
title |
Plasma convalescente como alternativa ao tratamento aplicado à Covid-19 |
spellingShingle |
Plasma convalescente como alternativa ao tratamento aplicado à Covid-19 dos santos, Isabela Barbosa |
title_short |
Plasma convalescente como alternativa ao tratamento aplicado à Covid-19 |
title_full |
Plasma convalescente como alternativa ao tratamento aplicado à Covid-19 |
title_fullStr |
Plasma convalescente como alternativa ao tratamento aplicado à Covid-19 |
title_full_unstemmed |
Plasma convalescente como alternativa ao tratamento aplicado à Covid-19 |
title_sort |
Plasma convalescente como alternativa ao tratamento aplicado à Covid-19 |
author |
dos santos, Isabela Barbosa |
author_facet |
dos santos, Isabela Barbosa Vieira Borrasca , Julia Rodrigues Tiera, Lara de Oliveira Garcia, Larissa Guidorizzi Advíncula , Marina Giachini Segantini, Thainá Marques de Mendonça, Thaís Marques Chiari-Andréo, Bruna Galdorfini |
author_role |
author |
author2 |
Vieira Borrasca , Julia Rodrigues Tiera, Lara de Oliveira Garcia, Larissa Guidorizzi Advíncula , Marina Giachini Segantini, Thainá Marques de Mendonça, Thaís Marques Chiari-Andréo, Bruna Galdorfini |
author2_role |
author author author author author author author |
dc.contributor.author.fl_str_mv |
dos santos, Isabela Barbosa Vieira Borrasca , Julia Rodrigues Tiera, Lara de Oliveira Garcia, Larissa Guidorizzi Advíncula , Marina Giachini Segantini, Thainá Marques de Mendonça, Thaís Marques Chiari-Andréo, Bruna Galdorfini |
description |
COVID-19 is an infectious disease that has spread rapidly around the world, characterizing a pandemic. Its etiologic agent is SARS-CoV-2, which promotes respiratory infections, mainly with symptoms equivalent to the common cold, but also complications, especially in patients with comorbidities. So far, there are no reports of medication, available to the population, capable of controlling the proliferation of the virus. In this context, an alternative that emerges and is also being discussed is the use of convalescent plasma (CP). Therefore, this study aimed to present a possible therapeutic resource for the care of patients infected with SARS-CoV-2 using CP, based on evidences from the literature. To achieve this goal, databases, such as Google Scholar, Scielo, Science Direct and PubMed, were used to search for evidences. Among the keywords used can be mentioned: “Coronavirus”, “COVID-19”, “SARS-CoV-2”, “convalescent plasma” isolated or in combination. The CP consists of plasma from patients who have already had the disease and recovered, serving as a source of specific antibodies of human origin, since there was the development of humoral immunization against the infectious agent. Therefore, in this case, the intention is to perform a CP transfusion for patients who are sick, neutralizing the pathogen and eventually leading to its eradication of blood circulation, since the antibody circulates in the blood, reaches tissues and protects against infections. There are not many studies available in the literature on the topic yet, but they already show promising results, including those associated with previous evidence of other viral infections such as Ebola, H5N1, H1N1 and measles. It is concluded that convalescent plasma may be a potential therapy for patients infected with SARS-CoV-2 with the highest risk involved. Serious adverse reactions associated with the use of CP have not been described, but an improvement in the condition compared to no treatment. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-09-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://revistarebram.com/index.php/revistauniara/article/view/1153 10.25061/2527-2675/ReBraM/2020.v23i3.1153 |
url |
http://revistarebram.com/index.php/revistauniara/article/view/1153 |
identifier_str_mv |
10.25061/2527-2675/ReBraM/2020.v23i3.1153 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
http://revistarebram.com/index.php/revistauniara/article/view/1153/645 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Revista Brasileira Multidisciplinar - ReBraM |
publisher.none.fl_str_mv |
Revista Brasileira Multidisciplinar - ReBraM |
dc.source.none.fl_str_mv |
Revista Brasileira Multidisciplinar - ReBraM; v. 23 n. 3 (2020): Setembro-Dezembro; 244-258 2527-2675 1415-3580 reponame:Revista Brasileira Multidisciplinar instname:Universidade de Araraquara (UNIARA) instacron:UNIARA |
instname_str |
Universidade de Araraquara (UNIARA) |
instacron_str |
UNIARA |
institution |
UNIARA |
reponame_str |
Revista Brasileira Multidisciplinar |
collection |
Revista Brasileira Multidisciplinar |
repository.name.fl_str_mv |
Revista Brasileira Multidisciplinar - Universidade de Araraquara (UNIARA) |
repository.mail.fl_str_mv |
revistauniara@uniara.com|| |
_version_ |
1797174607143239680 |